Hadassah

“Stunning Results” Continue with Hadassah’s Stem Cell Treatment to Reverse MS

Thursday, Sep 15 2016

Prof. Dimitrios Karussis.

The Hadassah Medical Center is continuing to receive positive findings with its Phase II clinical trial using its unique stem cell approach to stop the progression and reversing the disabilities of multiple sclerosis.

The Hadassah-developed treatment involves intrathecal injection--injection of the patient’s own bone marrow-derived stem cells directly into the spinal fluid--so that the cells circulate all the way around the brain and the spinal cord, where they are needed.

Hadassah began its clinical trials with ALS and MS patients in 2007, marking “the first time this approach had been applied in neurological diseases,” explains Principal Investigator Prof. Dimitrios Karussis, head of Hadassah’s Multiple Sclerosis Center. “The safety data were excellent,” he relates. “There was absolutely no serious adverse event, and we saw that, as a secondary observation-- because there was no placebo with which to compare it --patients with ALS stopped progressing for at least six months, the length of the study.”  In addition, he says, “patients with multiple sclerosis sometimes had a significant improvement in their disability.”

Fast forward to 2016 and Prof. Karussis is now optimistic about his Phase II study which began in January 2015. To date, about 2/3 out of the 48 patients to be enrolled have been recruited and treated. “This trial,” explains Prof. Karussis, “is a large, randomized double-blind, placebo-controlled study. While the patients in the control group will not know if they are initially getting the actual treatment or a placebo, the trial contains a crossover design so that eventually everyone will get the stem cell treatment, although some patients will receive the actual treatment six months later.”

Where will these clinical trials lead if they continue to yield positive findings? Prof. Karussis replies:  “We can say that if things continue to go like this and continue in the same direction, this will definitely change the face of neurology and the management of these diseases, which have been very impotent, you could say, all these years.”  Read the full article in The Jerusalem Post

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Sep 28 2016

Hadassah Medical Organization Goes on High Alert for Peres Funeral

Thousands of visitors, including high profile dignitaries, are expected to arrive in Jerusalem for the funeral of past Prime Minister and President Shimon Peres, who will be laid to rest on Friday, September 30.

READ MORE ›
alt_text

Friday, Sep 23 2016

2016 Graduates from 19 Countries Celebrate Hadassah’s IMPH Program

Singing "It's a Wonderful Country" in Hebrew, wearing their native dress, the members of the 41st International Master of Public Health (IMPH) program of the Hadassah-Hebrew University Braun School of Public Health and Community Medicine celebrated their graduation.

READ MORE ›
alt_text

Monday, Sep 19 2016

Hadassah Hospital Treats Terror Victims After Stabbing Attacks

This last week has brought a burst of terror attacks.

READ MORE ›
alt_text

Thursday, Sep 15 2016

2012 Hadassah Stage-Four Melanoma Patient Thankfully Healthy

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said Hadassah melanoma patient Stewart Greenberg.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More